Is Acalabrutinib made by AstraZeneca?

Acalabrutinib is a drug developed and produced by AstraZeneca (AstraZeneca). AstraZeneca is a global pharmaceutical company dedicated to developing and manufacturing innovative medicines to treat a variety of diseases, including cancer, cardiovascular disease, respiratory diseases and more.

Acotinib is a brutenib (BTK) inhibitor used to treat B cell-related malignant lesions, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This class of drugs plays a key role in cancer treatment, blocking the growth and spread of cancer cells by inhibiting specific signaling pathways.

AstraZeneca’s scientific research and production teams are committed to continuously pushing the boundaries of medical technology and providing more innovative and effective treatment options. The development and production of acotinib is one of AstraZeneca's important achievements in the field of cancer, providing patients with a more precise and targeted treatment option.

It should be noted that information in the field of drug development and production may be updated and changed. Therefore, when looking for the latest relevant information, it is recommended to consult the latest medical literature, drug instructions, or consult a medical professional.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.